Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 22, 2011, Pages 6804-6807

  Li, Yang Biao ^a   Xie, Yun Ying ^a   Du, Na Na ^a   Lu, Yu ^b   Xu, Hong Zhang ^a   Wang, Bin ^b   Yu, Ying ^a   Liu, Yan Xin ^a   Song, Dan Qing ^a   Chen, Ru Xian ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antitubercular; Drug resistance; Sansanmycin; Structure activity relationship; Uridyl peptide

Indexed keywords

ISONIAZID; RIFAMPICIN; SANSANMYCIN A; SANSANMYCIN B; SANSANMYCIN F; SANSANMYCIN G; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; URIDINE PHOSPHATE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTITUBERCULAR ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CHINA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OLIGOPEPTIDES; STREPTOMYCES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; URIDINE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 80054733585     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.031     Document Type: Article

References (21)

1. WHO. Tuberculosis, Fact Sheet No. 104; 2010.
2. WHO. Tuberculosis, Tuberculosis Global Facts; 2010/2011.
3. WHO Global Tuberculosis Control Report; 2004.
4. H. Tomioka Curr. Pharm. Des. 12 2006 4047
5. M. Spigelman J. Infect. Dis. 196 2007 S28
6. Y. Xie, R. Chen, S. Si, C. Sun, and H. Xu J. Antibiot. (Tokyo) 60 2007 158
7. Y. Xie, R. Chen, S. Si, C. Sun, and H. Xu J. Antibiot. (Tokyo) 61 2008 237
8. Y. Xie, H. Xu, C. Sun, Y. Yu, and R. Chen J. Antibiot. (Tokyo) 63 2010 143
9. F. Isono, M. Inukai, S. Takahashi, T.J. Haneishi, and R. Chen J. Antibiot. (Tokyo) 42 1989 667
10. R.H. Chen, A.M. Buko, D.N. Whittern, and J.B. McAlpine J. Antibiot. (Tokyo) 42 1989 512
11. S. Chatterjee, S.R. Nadkarni, E.K. Vijayakumar, M.V. Patel, B.N. Ganguli, H.W. Fehlhaber, and L. Vertesy J Antibiot. 47 1994 595
12. C.G. Boojamra, R.C. Lemoine, J. Blais, N.G. Vernier, K.A. Stein, A. Magon, S. Chamberland, S.J. Hecker, and V.J. Lee Bioorg. Med. Chem. Lett. 13 2003 3305
13. K. Kimura, and T.D. Bugg Nat. Prod. Rep. 20 2003 252
14. M. Inukai, F. Isono, and A. Takatsuki Antimicrob. Agents Chemother. 37 1993 980
15. T.D. Bugg, A.J. Lloyd, and D.I. Roper Infect. Disord. Drug Targets 6 2006 85
16. C. Dini Curr. Top. Med. Chem. 5 2005 1221
17. L.A. Collins, and S.G. Franzblau Antimicrob. Agents Chemother. 41 1997 1004
18. C.A. Gentle, S.A. Harrison, M. Inukai, and T.D. Bugg J. Chem. Soc., Perkin Trans. 1 1999 1287
19. N.I. Howard, and T.D. Bugg Bioorg. Med. Chem. 11 2003 3083
20. 3), a flow rate at 5 mL/min, UV detection at 254 nm and oven temperature at 40 °C.
21. 6): δ 0.75-1.08 (9H, m), 1.97 (3H, s), 2.35 (2H, m), 2.41-2.64 (3H, m), 2.69 (2.87) (3H, s), 2.74-2.84 (2H, m), 3.01 (1H, t), 2.95 (1H, t), 3.87-4.77 (6H, m), 5.64 (5.46) (1H, d), 5.96 (5.92) (1H, br s), 5.77 (5.76) (1H, br s), 6.41-6.69 (3H, m), 6.91-7.15 (4H, m), 7.27 (1H, br), 7.40-7.71 (2H, m).